The Global Research Antibodies Market (including reagents) is projected to reach USD 12.60 billion by 2022 from USD 9.33 billion in 2017, at a CAGR of 6.2%. Factors such as the increasing R&D activities and expenditure in the life science sector, increasing funding for proteomics research and drug development, and growing collaboration between industries and academic institutes are the key drivers of this market.
Browse 187 Market Data Tables and 42 Figures spread through 279 Pages and in-depth TOC on “Research Antibodies Market“.
In this report, the market is segmented on the basis of product, technology, application, end user, and region.
Based on technology, the research antibodies market is segmented into western blotting, flow cytometry, ELISA, immunohistochemistry, immunofluorescence, immunoprecipitation, and others (electrophoresis, bio-imaging, and microarrays). The flow cytometry segment is expected to grow at the highest rate during the forecast period.
On the basis of product, the research antibodies market (including reagents) is segmented into reagents and antibodies. The antibodies segment is expected to register the highest CAGR during the forecast period. The growth of this segment is primarily attributed to their high specificity, selectivity, and affinity, which make them highly desirable tools in fundamental and applied research.
Download PDF Brochure: – https://www.marketsandmarkets.com/pdfdownload.asp?id=94212793
On the basis of application, the research antibodies market is segmented into proteomics, drug development, and genomics. The drug development segment is expected to grow at the highest CAGR during the forecast period. The increasing demand for personalized medicine and increasing government initiatives in this sector are the key market drivers for this segment.
Based on end user, the market has been segmented into pharmaceutical & biotechnological companies, academic & research institutes, and contract research organizations.
Geographically, the global research antibodies market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Growth in this regional segment is largely driven by the growing proteomics and genomics research & increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics.